Treatment of Lupus Nephritis with 15-Deoxyspergualin
Author Information
Author(s): Lorenz Hanns-Martin, Schmitt Wilhelm H, Tesar Vladimir, Müller-Ladner Ulf, Tarner Ingo, Hauser Ingeborg A, Hiepe Falk, Alexander Tobias, Woehling Heike, Nemoto Kyuichi, Heinzel Peter A
Primary Institution: University Hospital Heidelberg
Hypothesis
The study aimed to evaluate the safety of 15-deoxyspergualin in the treatment of lupus nephritis.
Conclusion
The study demonstrated that 15-deoxyspergualin provides a tolerably safe treatment for lupus nephritis, with significant improvement in proteinuria.
Supporting Evidence
- Proteinuria decreased from 5.88 g/day to 3.37 g/day after treatment.
- Eleven out of 20 patients achieved partial or complete responses.
- Adverse events included infections and leukopenia, but most were mild.
Takeaway
Doctors tested a new medicine called 15-deoxyspergualin to help kids with kidney problems from lupus, and it seemed to work pretty well without making them too sick.
Methodology
Patients with active lupus nephritis were treated with 15-deoxyspergualin for up to nine cycles, with doses adjusted based on response and side effects.
Potential Biases
Potential bias due to the open-label design and lack of randomization.
Limitations
The small sample size and lack of a control group limit the conclusions that can be drawn about the efficacy of 15-deoxyspergualin.
Participant Demographics
The study included 21 patients, predominantly Caucasian, with a mean age of 31.3 years; 3 males and 17 females.
Statistical Information
P-Value
0.028
Statistical Significance
p=0.028
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website